Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical Co (OTCPK:RPHCF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Rohto Pharmaceutical Co Forward PE Ratio Related Terms
Rohto Pharmaceutical Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co Forward PE Ratio Chart
Rohto Pharmaceutical Co Annual Data
Trend
2025-03
2026-03
Forward PE Ratio
20.11
16.00
Rohto Pharmaceutical Co Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
20.98
20.11
15.27
15.27
17.19
16.00
RPHCF vs PG, CL, KVUE: Forward PE Ratio Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Forward PE Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Forward PE Ratio falls into.
Rohto Pharmaceutical Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Rohto Pharmaceutical Co (RPHCF) has a Forward PE Ratio of 15.61 as of Jul. 22, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Rohto Pharmaceutical Co and its competitors. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #428 out of 745 companies in the Consumer Packaged Goods industry, placing it in the top 57.4%.
Is Rohto Pharmaceutical Co's Forward PE Ratio too high?
Rohto Pharmaceutical Co's current Forward PE Ratio is 15.61. The Consumer Packaged Goods industry median Forward PE Ratio is 14.33. Rohto Pharmaceutical Co's value of 15.61 is 8.9% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #428 out of 745 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Forward PE Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #428 out of 745 companies for Forward PE Ratio. This places Rohto Pharmaceutical Co in the lower half of its industry. The industry median Forward PE Ratio is 14.33. Rohto Pharmaceutical Co's value of 15.61 is 8.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Consumer Packaged Goods company?
The median Forward PE Ratio among Consumer Packaged Goods companies is 14.33, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Forward PE Ratio of 15.61 is 8.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Forward PE Ratio is 14.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Forward PE Ratio is 15.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current Forward PE Ratio of 15.61. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current Forward PE Ratio is 15.61 and 8.9% above the Consumer Packaged Goods industry median of 14.33. Rohto Pharmaceutical Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current Forward PE Ratio is 15.61 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.
Key valuation signals for RPHCF:
Forward PE Ratio: 15.61
GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
Industry Position: 8.9% above the Consumer Packaged Goods median (#428 of 745)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
89GF Score
Get the complete analysis for RPHCF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
